Ribavirin therapy: implementation of hospital guidelines and effect on usage and cost of therapy

Clicks: 417
ID: 111529
1995
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Star

Ranked #37 of 581 articles by views in pediatrics

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 581 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Before the implementation of hospital guidelines for use, a substantial percent of patients received ribavirin not consistent with the recommendations of the AAP. Following the adoption of a modified version of the AAP guidelines for our institution and the use of a multidisciplinary surveillance sy …
Reference Key
tj1995pediatricsribavirin Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Feldstein TJ;Swegarden JL;Atwood GF;Peterson CD;;
Journal pediatrics
Year 1995
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/7596703
Keywords
medical National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine Infant newborn United States pediatrics ribavirin / therapeutic use* practice guidelines as topic respiratory syncytial virus infections / drug therapy* pmid:7596703 t j feldstein j l swegarden c d peterson drug costs drug utilization review* ribavirin / economics societies

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.